No Data
Hutchmed Projects Gain of $477 Million From Hutchison Pharmaceutical Stake Disposal
[Hong Kong Stock Connect] Hutchmed (China) (00013) rose 5.76% against the market trend as the company's new lung cancer drug application was approved and granted priority review.
Jingu Financial News | Hutchmed (China) (00013) rose against the market trend at the beginning of trading, as of press time, it was up 5.76%, trading at HKD 23.85, with a turnover of HKD 94.2265 million. The company announced that the combination therapy of orpathys (savolitinib) and tagrisso (osimertinib) is used to treat EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients who progress after first-line epidermal growth factor receptor (EGFR) inhibitor treatment with MET amplification.
HUTCHMED's Lung Cancer Drug Combo Gains Priority Review
Hutchmed Announces NDA Acceptance in China, Payment From AstraZeneca
Hutchmed (China) (00013.HK) announced that the new drug application for the combined therapy of Orpathys and Tagrisso for the treatment of lung cancer patients with disease progression after first-line EGFR inhibitor treatment with MET amplification has b
Gelonghui, January 2nd丨Hutchmed (00013.HK) announced today that the new drug application for the combination therapy of Orpathys (savolitinib) and Tagrisso (osimertinib) for the treatment of EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients with MET amplification who have progressed after first-line epidermal growth factor receptor ("EGFR") inhibitor treatment has been accepted and prioritized by China's National Medical Products Administration ("NMPA").
Express News | HUTCHMED (China) Ltd - This Acceptance Also Triggers a Milestone Payment From AstraZeneca
